Merck and New Jersey-based Nectin Therapeutics announced a research collaboration agreement Tuesday to study the safety and efficacy of Nectin’s investigational antibody NTX1088 in locally advanced and metastatic solid tumors.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,